Decision Resources, Inc., May 2011
in Japan: forthcoming review of the impact of the premium for new drug development and elimination of off-label drug use.
- Legislation: American Recovery and Reinvestment Act of 2009 (ARRA); Department
Decision Resources, Inc., Aug 2007, Pages: 22
population across all markets. What are the advantages and disadvantages for drug developers? What effect does orphan-drug status have on a drug’s potential?
-No therapies are approved specifically for HD; all
Business Monitor International, Feb 2010, Pages: 87
professionals, with the Therapeutic Goods Administration (TGA) publishing more medicine information on its website. In a related development, the Australian Competition and Consumer Commission (ACCC) authorised
John Wiley and Sons Ltd, Jan 2011, Pages: 520
This book is a compilation of summarized analytical methods designed to serve the needs of pharmacologists, toxicologists, and other allied health professionals involved the development, use